Galecto raises €79M to run late-phase IPF trial

Galecto Biotech has raised €79 million ($90 million) to take its treatment for idiopathic pulmonary fibrosis (IPF) into a phase 2/3 trial.

CFO-karrusel: To danske biotekfirmaer får nye finanschefer

To danske biotekselskaber får nye mænd til at styre finanserne. Den ene er samtidigt finansdirektør for et tredje dansk selskab med rødder i Novozymes.

Video: BIO-Europe® 2018_ Galecto Biotech's CMO discusses the company's recent EUR 79m Series C financing

Richard Marshall, chief medical officer at Galecto Biotech, talks to Scrip managing editor Joe Shorthouse about how a recent financing will allow the galectin modulator company to quickly push forward its product for idiopathic pulmonary fibrosis. He also discusses the company's work in the oral and ocular therapeutic areas.